List of Excipients in Branded Drug TOUJEO

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	TOUJEO MAX	insulin glargine	50090-4177	GLYCERIN
A-S Medication Solutions	TOUJEO MAX	insulin glargine	50090-4177	METACRESOL
A-S Medication Solutions	TOUJEO MAX	insulin glargine	50090-4177	WATER
A-S Medication Solutions	TOUJEO MAX	insulin glargine	50090-4177	ZINC

# Toujeo Excipient Strategy and Commercial Opportunities for Insulin Glargine U-300

Last updated: October 24, 2026

Toujeo is Sanofi’s concentrated insulin glargine product, supplied at 300 units/mL for once-daily subcutaneous administration. Its commercial and technical differentiation depends on the interaction between insulin glargine concentration, acidic formulation, zinc, preservatives, tonicity agents, surfactant control, and the SoloStar or Max SoloStar delivery system. The most attractive excipient opportunities are in high-purity zinc, m-cresol, polysorbate 20, container-closure compatibility, analytical testing, and follow-on insulin manufacturing rather than in substituting the formulation with a conventional excipient package.

What is Toujeo and how does its excipient strategy work?

Toujeo contains insulin glargine U-300, an engineered insulin analog formulated at three times the concentration of Lantus U-100. The product is an acidic solution with a nominal pH of 4.0. After subcutaneous injection, insulin glargine forms microprecipitates at physiological pH. These deposits release insulin gradually over an extended period.

Toujeo formulation profile

Formulation element	Publicly reported role
Insulin glargine	Active recombinant insulin analog
Concentration	300 units/mL
Zinc chloride	Supports insulin association, stability and precipitation behavior
m-Cresol	Antimicrobial preservative
Glycerol	Tonicity and formulation support
Polysorbate 20	Surfactant used to limit interfacial adsorption and aggregation
Hydrochloric acid or sodium hydroxide	pH adjustment
Water for injection	Vehicle
Target pH	Approximately 4.0

Sanofi’s U.S. prescribing information identifies glycerol, m-cresol, zinc chloride, polysorbate 20, hydrochloric acid, sodium hydroxide and water for injection as inactive ingredients in Toujeo [1]. The precise commercial value of each component depends on its effect on insulin stability, precipitation kinetics, preservative performance, device compatibility and patient tolerability.

Toujeo’s excipient strategy is therefore functional rather than cosmetic. A change in zinc level, surfactant grade, preservative concentration or tonicity can alter the pharmacokinetic profile and may create a clinically relevant difference from the reference product.

What excipients protect the commercial performance of Toujeo?

The principal excipient protection is created by the formulation as a combination, not by any single ingredient.

Zinc chloride

Zinc is central to insulin self-association and crystallization behavior. In Toujeo, zinc concentration must be controlled tightly because the product is designed to form a sustained-release depot after injection. Zinc purity, chloride balance, trace-metal profile and lot-to-lot consistency are potential supplier differentiators.

Commercial opportunities include:

• Pharmaceutical-grade zinc chloride with low heavy-metal content.
• Validated control of zinc concentration at microgram-per-milliliter levels.
• Supply contracts with dual-source qualification.
• Stability studies demonstrating compatibility with insulin glargine and the primary container.
• Analytical methods for free zinc, total zinc and zinc-associated insulin species.

A supplier that can document low extractables, consistent particle-free delivery and validated elemental impurity control may have greater negotiating leverage than a commodity zinc supplier.

m-Cresol

m-Cresol is the principal antimicrobial preservative identified in the Toujeo label. It must maintain antimicrobial activity without causing unacceptable local irritation or destabilizing insulin.

Potential value drivers are:

• High chemical purity.
• Low aldehyde and phenolic impurity levels.
• Reliable supply for sterile injectable production.
• Compatibility with elastomeric components and pen reservoirs.
• Demonstrated preservative efficacy in the finished product.

m-Cresol supply is more defensible when linked to a complete preservative-control package, including assay, impurity characterization, microbial limits and container-closure studies.

Polysorbate 20

Polysorbate 20 reduces adsorption of insulin to manufacturing equipment, glass, polymeric surfaces and air-liquid interfaces. It also can reduce aggregation caused by agitation or filling operations.

Polysorbate 20 creates several technical risks:

• Oxidation and hydrolysis during storage.
• Peroxide generation.
• Lot variability in fatty-acid composition.
• Interaction with stainless steel, filters and elastomers.
• Potential effects on subvisible particles and insulin aggregates.

The strongest commercial opportunity is not simply selling polysorbate 20. It is providing a qualified grade with peroxide control, fatty-acid profiling, container compatibility data and a supply-chain stability package.

Glycerol and pH modifiers

Glycerol supports tonicity and contributes to the injectable formulation’s physical properties. Hydrochloric acid and sodium hydroxide establish the acidic pH required before administration.

These components are less likely to provide standalone patent differentiation. Their value is tied to:

• Sterile injectable grade.
• Low endotoxin profile.
• Consistent osmolality.
• pH stability over shelf life.
• Compatibility with insulin adsorption controls.

What formulation patents may protect Toujeo?

Toujeo protection is likely to rely on a combination of product, formulation, manufacturing, delivery-device and method-of-use rights.

Protection category	Relevance to Toujeo
Insulin glargine composition patents	Protect the active insulin analog or sequence-related subject matter
Concentrated insulin formulations	May address U-300 concentration, excipient ratios or depot behavior
Manufacturing patents	May cover expression, purification, crystallization, sterile filtration or filling
Device patents	May cover pen dose-conversion, cartridge geometry and delivery mechanics
Method-of-use patents	May address once-daily dosing, glycemic control or hypoglycemia reduction
Combination patents	May cover insulin glargine with other diabetes therapies or delivery systems

The excipient opportunity is strongest where a formulation claim specifies a combination of insulin glargine, zinc, preservative, surfactant, tonicity agent and pH range. A claim directed only to a commercially available excipient, such as glycerol or polysorbate 20, would generally provide weaker exclusionary value because those materials are widely used in injectable products.

A competitor could avoid a narrow formulation claim by using a different surfactant, preservative system, zinc level or concentration. That approach would still require proof of comparable stability, delivery performance and clinical behavior.

When does Toujeo lose exclusivity?

Toujeo’s commercial exclusivity has multiple layers. FDA approval occurred in March 2015, and the product is an insulin biologic rather than a conventional small-molecule drug for purposes of current U.S. regulatory pathways [2].

Exclusivity and patent timing

Item	Public position
U.S. approval	March 2015
Active ingredient	Insulin glargine U-300
Reference sponsor	Sanofi
Regulatory category	Biologic product approved under the insulin framework
U.S. follow-on pathway	Potentially abbreviated biologic application under section 351(k)
Patent expiry	Must be assessed patent-by-patent, including terminal disclaimers and regulatory adjustments
Regulatory exclusivity	Depends on applicable biologic exclusivity rules and approval history
Device protection	May continue independently of drug formulation protection

The U.S. transition of insulin products from the Federal Food, Drug, and Cosmetic Act to the Public Health Service Act occurred on March 23, 2020 [3]. As a result, a follow-on manufacturer must assess both historical NDA-era rights and current biologic patent and regulatory rules.

What is the Orange Book status of Toujeo?

Toujeo was originally approved through NDA 204629. Because insulin products transitioned into the biologic framework, Orange Book analysis alone does not provide a complete view of Toujeo’s current competitive barriers. The FDA’s Purple Book, patent disclosures under the Biologics Price Competition and Innovation Act, USPTO records and litigation databases are relevant to a follow-on program [3,4].

A commercial diligence review should distinguish:

1. Patents listed against the historical NDA.
2. Patents covering insulin glargine or concentrated insulin formulations.
3. Device patents covering SoloStar and Max SoloStar systems.
4. Manufacturing patents not necessarily visible through the Orange Book.
5. Method-of-use patents with limited enforceability against an interchangeable or biosimilar product.

Which companies are challenging Toujeo exclusivity?

The competitive field includes insulin manufacturers with experience in biosimilar, follow-on or noninterchangeable insulin products. Relevant companies include Eli Lilly, Biocon, Wockhardt, Ypsomed, Gan & Lee Pharmaceuticals, Julphar and other regional insulin manufacturers.

The commercial challenge is technical. A follow-on product must address:

• Insulin glargine primary structure and higher-order characteristics.
• Concentration at 300 units/mL.
• Pharmacokinetic and pharmacodynamic comparability.
• Injection-volume differences.
• Precipitation and depot-release behavior.
• Pen-device dose accuracy.
• Preservative and surfactant compatibility.
• Immunogenicity.
• Human factors and labeling.

Lantus biosimilar and follow-on activity does not automatically establish a Toujeo substitute. U-100 and U-300 insulin glargine products have different injection volumes, concentration-dependent pharmacology and device presentations.

What generic launch risks exist for Toujeo?

Toujeo has a higher entry barrier than a conventional injectable generic. The primary risks are formulation sameness, device comparability, clinical requirements and patent enforcement.

Generic and follow-on launch scenarios

Launch scenario	Commercial implication
Exact U-300 formulation and compatible pen	Highest potential for direct substitution, but highest patent and technical exposure
U-300 formulation with different excipient system	May avoid selected formulation claims but requires comparability work
U-100 insulin glargine competitor	Competes with Lantus, not directly with Toujeo’s concentrated presentation
Vial-based U-300 product	May reduce device costs but could lose convenience and dose-selection advantages
Cartridge or reusable-pen product	May target payers or price-sensitive markets
Noninterchangeable follow-on biologic	May require prescriber acceptance and face pharmacy substitution limits
Interchangeable biologic	Greater substitution potential if FDA requirements are met

A successful competitor must also manage the risk of dosing errors. Toujeo pens are calibrated to deliver insulin units rather than requiring patients to calculate volume. A non-equivalent pen architecture could create medication-error concerns and additional regulatory scrutiny.

How strong is Toujeo’s patent estate?

Toujeo’s patent estate is strongest where formulation, concentration, device and manufacturing claims overlap. Its practical strength is lower if protection depends primarily on expired insulin glargine composition patents or narrow method-of-use claims.

Patent-strength assessment

Patent layer	Relative commercial strength
Active insulin glargine composition	Potentially strong historically, but age and expiry are critical
U-300 concentration and depot formulation	Strong if claims cover the formulation broadly
Excipient combination	Moderate to strong when specific ratios and performance are claimed
Pen delivery system	Strong against identical or highly similar devices
Manufacturing process	Strong if difficult to design around and not readily visible
Method of use	Variable, depending on claim scope and infringement pathway
Standalone excipient claims	Generally weaker because ingredients are widely available

Sanofi’s most durable practical protection may come from the combination of formulation know-how, device integration, manufacturing controls, regulatory data and payer relationships. These barriers can delay entry even when individual composition patents are approaching expiration.

What manufacturing and excipient barriers affect Toujeo competitors?

The manufacturing process must preserve insulin quality from fermentation through purification, formulation, filling and device assembly. U-300 production also requires control of concentrated insulin behavior during mixing and storage.

Key barriers include:

• Protein aggregation during pumping and filtration.
• Adsorption to process-contact surfaces.
• Surfactant degradation.
• Zinc association and precipitation control.
• Sterile filtration yield.
• Particulate control.
• Pen reservoir compatibility.
• Long-term stability after filling.
• Dose accuracy across the pen’s shelf life.
• Cold-chain and distribution performance.

A supplier that provides excipient qualification, process-development support and analytical comparability can capture more value than one selling an isolated raw material. This is particularly true for polysorbate 20 and zinc chloride, where low-level impurities can affect protein stability and regulatory comparability.

What licensing opportunities exist around Toujeo excipients?

Publicly visible licensing information is generally more developed for insulin products, devices and regional commercialization than for individual Toujeo excipients. Excipient licensing opportunities are therefore more likely to be structured as supply, technology-transfer or formulation-support agreements.

Potential deal structures include:

1. Long-term supply agreements for pharmaceutical-grade polysorbate 20.
2. Dual-source qualification agreements for zinc chloride and m-cresol.
3. Joint development of low-peroxide surfactant grades.
4. Analytical-method licensing for insulin aggregation and particle testing.
5. Technology transfer for sterile filling and pen compatibility.
6. Regional licensing of follow-on U-300 insulin products.
7. Device partnerships for cartridges, reusable pens or autoinjector platforms.

The highest-value agreements will combine material supply with regulatory documentation, process validation and change-control commitments. Commodity pricing alone is unlikely to create durable margins.

How does Toujeo compare with Lantus and other basal insulins?

Product	Active ingredient	Concentration	Primary commercial distinction
Toujeo	Insulin glargine	300 units/mL	Concentrated, prolonged basal profile
Lantus	Insulin glargine	100 units/mL	Established U-100 insulin glargine
Tresiba	Insulin degludec	100 or 200 units/mL	Ultra-long-acting insulin degludec
Basaglar	Insulin glargine	100 units/mL	Follow-on insulin glargine
Semglee	Insulin glargine	100 units/mL	Follow-on and interchangeable insulin glargine product in the U.S.

Toujeo’s excipient strategy cannot be copied simply by increasing insulin concentration. The competitor must reproduce the intended release characteristics while maintaining acceptable viscosity, stability, preservative performance and injection behavior.

What revenue exposure does Toujeo create for Sanofi?

Toujeo is part of Sanofi’s diabetes franchise and competes in a basal-insulin market exposed to payer rebates, biosimilar entry, tender pricing and substitution. Revenue exposure is tied to:

• U-300 market share relative to U-100 insulin glargine.
• Pen adoption.
• Coverage by commercial insurers and public payers.
• Price erosion from follow-on insulin products.
• Patient switching between basal insulin classes.
• International tender outcomes.
• Device and cartridge patent duration.
• Manufacturing cost per delivered unit.

A direct U-300 competitor would pose greater risk than a U-100 insulin glargine entrant because it could target the same patient segment and delivery profile. Conversely, U-100 follow-on products may pressure Toujeo indirectly through formulary substitution and lower net pricing.

Key Takeaways

• Toujeo is insulin glargine U-300 formulated with zinc chloride, m-cresol, glycerol, polysorbate 20, pH modifiers and water for injection.
• Its excipient strategy controls precipitation, depot release, protein stability, preservation and device compatibility.
• Zinc, polysorbate 20 and m-cresol offer the strongest commercial opportunities for qualified suppliers.
• The most defensible supplier proposition combines excipient quality with analytical data, process support and regulatory documentation.
• Toujeo’s competitive barriers include formulation, manufacturing, device, regulatory and method-of-use rights.
• Orange Book analysis is incomplete because insulin products transitioned into the biologic framework in 2020.
• A follow-on U-300 product faces materially higher technical and regulatory barriers than a conventional generic injectable.
• The most credible launch strategies involve an integrated formulation, device and manufacturing program rather than an excipient substitution alone.

FAQs About Toujeo Excipient and Commercial Strategy

Is Toujeo a biosimilar or a generic insulin?

Toujeo is Sanofi’s reference insulin glargine U-300 product. A competing product may use a follow-on biologic or biosimilar pathway, depending on jurisdiction and regulatory classification. A conventional small-molecule generic pathway does not fully describe the U.S. regulatory position for insulin products after the 2020 transition.

Can a competitor replace polysorbate 20 in a Toujeo follow-on formulation?

Potentially, but the change would require evidence of comparable stability, aggregation control, particulate levels, preservative performance, device compatibility and clinical behavior. A replacement surfactant could also affect patent scope and regulatory comparability.

Which Toujeo excipient has the greatest supply-chain opportunity?

Polysorbate 20 has the greatest technical differentiation opportunity because peroxide levels, hydrolysis, fatty-acid composition and protein-interaction behavior can vary by grade. Zinc chloride and m-cresol also offer value when supplied with full injectable-grade qualification.

Are Toujeo and Lantus formulation patents interchangeable?

No. Toujeo uses insulin glargine at 300 units/mL, while Lantus uses 100 units/mL. Their concentration, injection volume, precipitation behavior, dosing presentation and potentially applicable patent claims differ.

What is the largest commercial risk to Toujeo?

The largest risk is an approved, competitively priced U-300 follow-on insulin with a reliable pen device and payer access. U-100 insulin glargine products create indirect pressure, but a technically comparable U-300 product would pose the most direct substitution threat.

References

1. Sanofi-Aventis U.S. LLC. (2024). Toujeo insulin glargine injection prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2015). Toujeo approval history and prescribing information, NDA 204629. Drugs@FDA.

3. U.S. Food and Drug Administration. (2020). Regulatory transition of insulin and other biological products under the Biologics Price Competition and Innovation Act. FDA.

4. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.